A Phase I Study of Vorinostat in Combination with Bortezomib in Patients with Advanced Malignancies

BACKGROUND: A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors. METHODS: Patients received vorinostat orally once daily on days 1–14...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Schelman, William R., Traynor, Anne M., Holen, Kyle D., Kolesar, Jill M., Attia, Steven, Hoang, Tien, Eickhoff, Jens, Jiang, Zhisheng, Alberti, Dona, Marnocha, Rebecca, Reid, Joel M., Ames, Matthew M., McGovern, Renee M., Espinoza-Delgado, Igor, Wright, John J., Wilding, George, Bailey, Howard H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901262/
https://ncbi.nlm.nih.gov/pubmed/24114121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0029-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi